Abstract：
Endomucin (MUC14), encoded by EMCN gene, is an O-glycosylated transmembrane mucin that is mainly found in venous endothelial cells (ECs) and highly expressed in type H vessels of bone tissue. Its main biological functions include promoting endothelial generation and migration through the vascular endothelial growth factor (VEGF) signaling pathway and inhibiting the adhesion of inflammatory cells to ECs. In addition, it induces angiogenesis and promotes bone formation. Due to the excellent functions of Endomucin in the above aspects, it provides a new research target for the treatment of vascular inflammatory-related diseases and bone diseases. Based on the current understanding of its function, the research of Endomucin mainly focuses on the above two diseases. As it is known, the progression of cancer is closely related to angiogenesis. Endomucin recently is found to be differentially expressed in a variety of tumors and correlated with survival rate. The biological role of Endomucin in cancer is opaque. This article introduces the research progress of Endomucin in vascular inflammatory-related diseases and bone diseases, discusses its application value and prospect in the treatment, and collects the latest research situation of Endomucin in tumors, to provide meaningful evidence for expanding the research field of Endomucin.
摘要：
Endomucin(MUC14),由EMCN基因编码，是一种O-糖基化的跨膜粘蛋白，主要存在于静脉内皮细胞（EC）中，并在骨组织的H型血管中高度表达。其主要生物学功能包括通过血管内皮生长因子（VEGF）信号通路促进内皮生成和迁移，抑制炎症细胞与ECs的粘附。此外,它诱导血管生成并促进骨形成。由于Endomucin在上述方面的优异功能，为血管炎症相关疾病和骨疾病的治疗提供了新的研究靶点。根据目前对其功能的理解，子宫内膜蛋白的研究主要集中在上述两种疾病上。众所周知,癌症的进展与血管生成密切相关。最近发现子宫内膜蛋白在多种肿瘤中差异表达，并与生存率相关。子宫内膜蛋白在癌症中的生物学作用是不清楚的。本文介绍了Endomucin在血管炎症相关疾病和骨疾病中的研究进展,探讨了其在治疗中的应用价值和前景,并收集了子宫内膜蛋白在肿瘤中的最新研究情况，以期为拓展Endomucin的研究领域提供有意义的证据。
